Some studies of preventive medicine
=====

GLP1 reduces cancer risks
--------------------------

* Wang L, Xu R, Kaelber DC, Berger NA. Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes. JAMA Netw Open. 2024;7(7):e2421305. doi:10.1001/jamanetworkopen.2024.21305
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2820833

* Lin, Cindy, et al. "Comparative risk of obesity-related cancer with glucagon-like protein-1 receptor agonists vs. bariatric surgery in patients with BMI≥ 35." (2024): 10508-10508.
(https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.10508)


GLP1 and non-alcoholic fatty liver
------------------------------------
* Nevola R, Epifani R, Imbriani S, Tortorella G, Aprea C, Galiero R,
Rinaldi L, Marfella R, Sasso FC. GLP-1 Receptor Agonists in
Non-Alcoholic Fatty Liver Disease: Current Evidence and Future
Perspectives. International Journal of Molecular Sciences. 2023;
24(2):1703. 

(https://www.mdpi.com/1422-0067/24/2/1703#)


GLP1 vs metformin
------------------

* Sørensen KK, Gerds TA, Køber L, et al. Comparing Glucagon-like peptide-1 receptor agonists versus metformin in drug-naive patients: A nationwide cohort study. J Diabetes. 2024;16(10):e70000. doi:10.1111/1753-0407.70000
(https://pubmed.ncbi.nlm.nih.gov/39364788/)

CEA
-----------
* Park JS, Choi GS, Jang YS, Jun SH, Kang H. Influence of obesity on the serum carcinoembryonic antigen value in patients with colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2010;19(10):2461-2468. doi:10.1158/1055-9965.EPI-10-0569
(https://pubmed.ncbi.nlm.nih.gov/20729287/)



